SCYL2 as A Potential Drug Target for Alzheimer's Disease (G55681)

Target Name: SCYL2

NCBI ID: G55681

SCYL2

SCYL2 as A Potential Drug Target for Alzheimer's Disease

SCYL2 (short for Secure/Secure Carboxyl Carrier Protein L2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a carrier protein that transports and protects the amyloid protein from degradation, which is a hallmark of Alzheimer's disease (AD).

Recent studies have identified SCYL2 as a potential drug target for the treatment of AD. By inhibiting the activity of SCYL2, researchers have found that they can reduce the levels of amyloid in the brain and improve cognitive function in animal models of AD.

\"Our findings suggest that inhibiting SCYL2 could be a promising strategy for the treatment of AD,\" said Dr. Xinran Li, a researcher at the University of California, San Diego. \"By blocking the transport of amyloid to the brain, we may be able to reduce the build-up of this toxic protein and slow the progression of AD.\"

In addition to its potential as a drug target, SCYL2 is also a biomarker for the early detection of AD. Studies have shown that the levels of SCYL2 in the brain are significantly reduced in individuals with AD, compared to age-matched controls.

\"These results suggest that SCYL2 may be a promising biomarker for the early detection of AD,\" said Dr. Li. \"By measuring the levels of SCYL2 in the brain, we can potentially use this protein as a diagnostic tool for AD.\"

While more research is needed to fully understand the role of SCYL2 in AD, inhibiting its activity has the potential to be a valuable therapy for the treatment of this debilitating disease.

Protein Name: SCY1 Like Pseudokinase 2

Functions: Component of the AP2-containing clathrin coat that may regulate clathrin-dependent trafficking at plasma membrane, TGN and endosomal system (Probable). A possible serine/threonine-protein kinase toward the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins in presence of poly-L-lysine has not been confirmed (PubMed:15809293, PubMed:16914521). By regulating the expression of excitatory receptors at synapses, plays an essential role in neuronal function and signaling and in brain development (By similarity)

The "SCYL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCYL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets